Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
32 stopped studies mapped to Non-Small Cell Adenocarcinoma and descendants · 97% state a reason
Over the 32 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06491225 | Autologous Tumor-Infiltrating Lymphocyte (GTE-001 Injection ) for Treatment of Patients… | Phase 1 | terminated | Jul 9, 2024 | Grit Biotechnology | The study was terminated from a business perspective. | Sponsor / business decision |
| NCT04432207 | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung… | Phase 1 | terminated | Jun 16, 2020 | Imugene Limited | Portfolio prioritization | Sponsor / business decision |
| NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2) | Phase 1 / Phase 2 | withdrawn | Oct 4, 2022 | Intima Bioscience, Inc. | No recruitment | Enrollment / accrual |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT03371381 | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes… | Phase 1 / Phase 2 | terminated | Dec 13, 2017 | Janssen Research & Development, LLC | Development of JNJ-64041757 in combination with nivolumab discontinued due to lack of clinical… | Efficacy / futility |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT04944173 | SCION: SABR and Checkpoint Inhibition of NSCLC(SCION) | Phase 2 | withdrawn | Jun 29, 2021 | University of British Columbia | Overestimated pool of eligible patients and the potential participants either declined… | Other (stated, no rule matched) |
| NCT04027946 | LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing… | Phase 2 | terminated | Jul 22, 2019 | National Cancer Institute (NCI) | Study was terminated due to slow accrual. | Enrollment / accrual |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With… | Phase 1 | terminated | Dec 23, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Dec 31, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive… | Early Phase 1 | withdrawn | May 3, 2021 | Roswell Park Cancer Institute | Issues recruiting | Enrollment / accrual |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in… | Phase 3 | terminated | Jul 27, 2009 | SWOG Cancer Research Network | terminated at pre-planned futility analysis | Efficacy / futility |
| NCT04861948 | IBI188 Combination Therapy in Solid Tumors | Phase 1 | terminated | Apr 27, 2021 | Innovent Biologics (Suzhou) Co. Ltd. | No signs of efficacy in solid tumors | Efficacy / futility |
| NCT03891173 | A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma | Phase 2 | terminated | Mar 26, 2019 | Helix BioPharma Corporation | Study was halted at this time due to other budgetary priorities. Completion of reporting has been… | COVID-19 / pandemic |
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or… | Phase 2 | terminated | Feb 2, 2017 | Nasser Hanna, M.D. | Funder decision - lack of accrual | Enrollment / accrual |
| NCT02621333 | Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV… | Phase 2 | terminated | Dec 3, 2015 | Henan Cancer Hospital | As there are so many clinical trials in progress and the number of patients enrolled limited. | Enrollment / accrual |
| NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC…(N3) | Phase 1 / Phase 2 | withdrawn | Dec 4, 2017 | Royal Marsden NHS Foundation Trust | Withdrawal of financial support from funder | Funding |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV… | Phase 2 | terminated | May 9, 2014 | SWOG Cancer Research Network | science has moved forward and there is no intent to complete the study | Other (stated, no rule matched) |
| NCT01707823 | Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung… | Early Phase 1 | terminated | Oct 16, 2012 | Vanderbilt-Ingram Cancer Center | Funding unavailable | Funding |
| NCT02466568 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | Phase 1 / Phase 2 | withdrawn | Jun 9, 2015 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT02891733 | Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung…(NTS) | — | withdrawn | Sep 7, 2016 | Fondation Hôpital Saint-Joseph | The principal investigator decided to stop the study. | Investigator |
| NCT01578551 | Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With… | Phase 2 | terminated | Apr 17, 2012 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Low enrollment | Enrollment / accrual |
| NCT00955305 | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients… | Phase 2 | terminated | Aug 10, 2009 | National Cancer Institute (NCI) | The study was closed to accrual due to the end of the clinical development program with cixutumumab. | Enrollment / accrual |
| NCT02121925 | Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in…(ONC003) | — | terminated | Apr 24, 2014 | Myriad Genetic Laboratories, Inc. | Company decision to terminate | Sponsor / business decision |
| NCT02715102 | Circulating Tumor DNA in Patients at High Risk for Lung Cancer | — | terminated | Mar 22, 2016 | Pathway Genomics | Patient accrual was slow due to exclusion of patients with prior cancers | Enrollment / accrual |
| NCT01819428 | NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma | Phase 2 | terminated | Mar 27, 2013 | National OncoVenture | Low recruitment | Enrollment / accrual |
| NCT02059967 | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients… | Phase 1 | withdrawn | Feb 11, 2014 | Virginia Commonwealth University | Due to no accrual. | Enrollment / accrual |
| NCT00369551 | Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating… | Phase 1 | terminated | Aug 29, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00042835 | Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00117351 | VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar… | Phase 2 | terminated | Jul 6, 2005 | Millennium Pharmaceuticals, Inc. | insufficient efficacy | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Apr 23, 2026source: clinicaltrials